Why the study?
Severe rhabdomyolysis can cause AKI and benefits from CRRT, but whether serum creatine kinase levels can guide CRRT termination remained unknown.
Does CRRT termination at CK > 5,000 U/L worsen clinical outcomes compared to CK < 5,000 U/L in patients with rhabdomyolysis-associated AKI?
Population
86 cases with confirmed rhabdomyolysis-associated AKI receiving CRRT in Tongji Hospital
Comparison
CK > 5,000 U/L vs CK < 5,000 U/L after CRRT termination
Design
Retrospective cohort study
Key result
In patients with rhabdomyolysis-associated AKI, serum CK > 5,000 U/L at CRRT termination was not associated with increased in-hospital mortality (p=0.389) compared to CK < 5,000 U/L.
Authors
Loading...
Early CRRT termination at CK >5,000 U/L may not worsen mortality or MODS in rhabdomyolysis-AKI; leaves open optimal CK-independent thresholds for randomized confirmation.
Cohort (n=86)
No
Does CRRT termination at CK > 5,000 U/L worsen clinical outcomes compared to CK < 5,000 U/L in patients with rhabdomyolysis-associated AKI?
p-value: p=0.389
CRRT termination in rhabdomyolysis-associated AKI can be safely performed based on renal function recovery, independent of serum creatine kinase levels.
Xiao et al. (2022) conducted a cohort in Rhabdomyolysis-associated acute kidney injury (n=86). Serum creatine kinase > 5,000 U/L vs. Serum creatine kinase < 5,000 U/L was evaluated on In-hospital mortality (p=0.389). In patients with rhabdomyolysis-associated AKI, serum CK > 5,000 U/L at CRRT termination was not associated with increased in-hospital mortality (p=0.389) compared to CK < 5,000 U/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: